Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial

Comparison of high‐dose dual therapy with bismuth‐containing quadruple therapy in Helicobacter pylori ‐infected treatment‐naive patients: An open‐label, multicenter, randomized controlled trial

(2022) Jia‐Lun Guan et al.   PHARMACOTHERAPY

Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial

(2022) William D. Chey et al.   GASTROENTEROLOGY

Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report

(2022) Peter Malfertheiner et al.   GUT

Reverse hybrid therapy achieves a similar eradication rate as standard hybrid therapy for Helicobacter pylori infection

(2020) Te-Fu Lin et al.   Journal of the Chinese Medical Association

PPI‐amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta‐analysis

(2020) Cai‐Ping Gao et al.   HELICOBACTER

Reverse hybrid and concomitant therapies are equivalent in efficacy for the first‐line treatment of H. pylori infection

(2020) Ping‐I Hsu et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus

(2020) Jyh-Ming Liou et al.   GUT

A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial

(2019) Wei-Chen Tai et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori

(2019) Jing Yang et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori

(2019) Takahisa Furuta et al.   DIGESTION

Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial

(2018) Ping-I Hsu et al.   Clinical Gastroenterology and Hepatology

Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale

(2017) Bor-Shyang Sheu et al.   HELICOBACTER

Helicobacter pylori management in ASEAN: The Bangkok consensus report

(2017) Varocha Mahachai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Optimized high-dose amoxicillin–proton-pump inhibitor dual therapies fail to achieve high cure rates in China

(2017) Dian-Chun Fang et al.   Saudi Journal of Gastroenterology

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

(2016) Carlo A. Fallone et al.   GASTROENTEROLOGY

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

(2016) Jyh-Ming Liou et al.   LANCET

High Dose Ilaprazole/Amoxicillin as First-Line Regimen forHelicobacter pyloriInfection in Korea

(2016) WonGun Kwack et al.   Gastroenterology Research and Practice

High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection

(2015) Jyh-Chin Yang et al.   Clinical Gastroenterology and Hepatology

Kyoto global consensus report onHelicobacter pylorigastritis

(2015) Kentaro Sugano et al.   GUT

Hybridvssequential therapy for eradication ofHelicobacter pyloriin Taiwan: A prospective randomized trial

(2015) Kuan-Yang Chen   WORLD JOURNAL OF GASTROENTEROLOGY

Hybrid therapy forHelicobacter pyloriinfection: A systemic review and meta-analysis

(2015) Ping-I Hsu   WORLD JOURNAL OF GASTROENTEROLOGY

High-Dose Extended-Release Lansoprazole (Dexlansoprazole) and Amoxicillin Dual Therapy forHelicobacter pyloriInfections

(2014) Taraq A. Attumi et al.   HELICOBACTER

Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance

(2013) Javier Molina–Infante et al.   GASTROENTEROLOGY

Comparison of Hybrid and Sequential Therapies forHelicobacter pyloriEradication in Iran: A Prospective Randomized Trial

(2012) Hossein Sardarian et al.   HELICOBACTER

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

(2012) Jyh-Ming Liou et al.   LANCET

Modified Sequential Helicobacter pylori Therapy: Proton Pump Inhibitor and Amoxicillin for 14 Days with Clarithromycin and Metronidazole added as a Quadruple (Hybrid) Therapy for the Final 7 Days

(2011) Ping-I. Hsu et al.   HELICOBACTER

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

(2011) Peter Malfertheiner et al.   LANCET

Guidelines for the Management ofHelicobacter pyloriInfection in Japan: 2009 Revised Edition

(2010) Masahiro Asaka et al.   HELICOBACTER

Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

(2009) E. Zucca et al.   ANNALS OF ONCOLOGY

Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying

(2008) W. Weitschies et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS